Therabody Patent Portfolio Analysis

The money lands on an existing crest

September 2022. A $165M round, announced as a single event. It reads, from outside, like the moment a company gains the means to invent. Held against Therabody's own filing record, it reads differently. By the month of the announcement the company had been filing at high volume for three straight years, and 2022 would close as its heaviest year on record. The capital did not start anything.

The first filing is dated 22 March 2017. For three years after that the record is almost silent: one family, then two, then two. Whatever was built in that period was built small. The 130 families now on file, 110 of them granted, were overwhelmingly begun after 2019 and mostly before the round. That sequence is the whole reason this piece exists.

The capital arrived at the crest, not before it.

One hundred and ten already through

Split the record by status and it is lopsided. 110 of the 130 families are granted. 20 remain published and pending. Eighty-five percent through is a high figure for a company whose first filing is dated 2017, and it tells you the claims here have mostly been examined rather than merely asserted. The wide ribbon is settled ground. The narrow one is everything still in motion.

A grant rate that high also means the pending side carries less of the story than usual. There is not a large speculative tail waiting to redefine what this company holds. What Therabody has, it largely already has, tested and issued across eight patent offices including the US, EP, CN, JP and KR. The interesting question moves from what might be granted to who wrote it.

Four years of climb, then a shaded edge

One family in 2017. Two in 2018. Two in 2019. Then 21 in 2020, 29 in 2021, and 44 in 2022. The step from two to twenty-one is the real event in this record, and it happens two years before the funding marker. Filing volume multiplied tenfold while the company was, on the evidence of the record alone, doing this without the round that later drew the headlines.

After the peak the bars fall: 21 in 2023, 6 in 2024, 4 in 2025. Read the last two with care. Filings publish on a delay, and the most recent published filing here is dated 18 November 2025, so the right-hand edge is necessarily incomplete. The 2023 drop to 21 is past the delay and real. The rest is not yet readable.

Ninety-nine dots, three that matter

Ninety-nine people are named as inventors across the file. The distribution is not remotely even. EDUARDO MERINO appears on 92 families. JAIME SANCHEZ SOLANA appears on 92. BENJAMIN NAZARIAN appears on 85. Against a total of 130, that means roughly seven of every ten families carry at least two of the same three names, through the silent years, through the 2022 peak, and out the other side.

That is unusual at this scale. A 130-family record built by a large engineering organisation normally fragments into teams, each with its own cluster of names and its own subject matter. Here it does not fragment. The recent published titles sit close together too: massage appliances, and articles of footwear having therapeutic assemblies. Consistent authorship, consistent subject. The concentration is the structure.

Two names appear on 92 of 130 families each.

Who points back at this work

Four organisations cite these filings with any frequency. MERCHSOURCE LLC accounts for 29 citations. HYDRAFACIAL LLC accounts for 17. PLAYMAKAR INC accounts for 15. SICHUAN QIANLI BEOKA MEDICAL TECH INC accounts for 10. Citations are not claims and prove nothing about anyone's business. What they do show is that examiners and applicants elsewhere keep arriving at this same body of work when they search.

Seventy-one citations from four names is a narrow, repeated pattern rather than diffuse background noise. It suggests the 2020 to 2022 families landed somewhere that others have since had to file through. For a record authored so consistently by three people, that outside attention is the clearest independent signal that the timing was early rather than merely busy.

What the sequence actually proves

Set the dates next to each other and the plain version is this. Therabody filed one family in 2017 and 44 in 2022. The climb began in 2020. The $165M was announced in September 2022, into a filing year already at its peak. Eighty-five percent of the resulting families are granted, and three people are named on almost all of them. Conviction preceded capital by two years.

That is a specific kind of moat. Not breadth of headcount, and not a large pending tail promising future scope, but a settled, examined record written by a small and unchanging group, filed across eight offices before the money made it obvious. The open part is what happens to that concentration now, on the shaded edge of the chart where the record cannot yet be read.